THE EFFECTS OF HONEY ADMINISTRATION ON SOLUABLE FMS-LIKE TYROSINE KINASE (SFLT-1), SOLUBLE ENDOGLIN (S-ENG), VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) SERUM LEVELIN THE RAT MODEL OF PREECLAMPSIA
Keywords:Honey, Soluble FMS-Like Tyrosine Kinase (sFlt-1), Soluble Endoglin (s-Eng), Vascular Endothelial Growth Factor (VEGF), Preeclampsia
Objective: To find out the effect of honey administration on changes in antiangiogenic and proangiogenic serum levels in the rat model of preeclampsia. This study is the first research that examines the effect of honey on preeclampsia especially on proangiogenic and antiangiogenic factors
Methods: This study uses analytic research with a quasi-experimental design in laboratory rats (Rattus Norvegicus) pregnant females given honey with concentration. The treatment of all samples was carried out simultaneously and during the treatment it was observed using the type of postest only control group design.
Results: Honey administration significantly reduced sFlt-1 levels in preeclampsia rats, and a greater dose of honey had an effect on strengthening the effect of honey in reducing sFlt-1 levels. Honey administration significantly increased VEGF levels in preeclampsia mice (p = 0.034). Honey administration significantly decreased s-Eng levels in preeclampsia mice, and administration of a larger dose of honey had an effect on strengthening the effect of honey in reducing s-Eng levels (p = 0.012).
Conclusion: The honey administration on rat’s model of preeclampsia may reduce the antiangiogenic level sFlt-1 and sEng dan increase VEGF level as the pro-angiogenic
2. Hariharan N, Shoemaker A, Wagner S. Pathophysiology of hypertension in preeclampsia. Clin Pract 2016;13:33-7.
3. Maynard SE, Karumanchi SA. Angiogenic factors and preeclampsia. Semin Nephrol 2011;31:33–46.
4. Andalas MH. Antagonis soluble fms-like tyrosine kinase 1 (sflt-1) dan soluble endoglin (seng) pada preeklamsia. JurnalIlmu Kedokteran 2010:1-9. Doi:10.26891/JIK.v4i1.2010
5. Nikuei P, Rajaei M, Malekzadeh L. Accuracy of soluble endoglin for diagnosis of preeclampsia and its severity. Iran Biomed J 2017;21:312-30.
6. Bates DO. An unexpected tail of vegf and plgf in pre-eclampsia. Biochem Soc Trans 2011;39:1576-82.
7. Rodriguez Barbero A, Obreo J, Eleno N, Rodriguez A, Bernabeu C, Lopez Novoa JM. Endoglin expression in human and rat mesangial cells and its upregulation by tgf-beta 1. Biochem Biophys Res Commun 2001;282:142–7.
8. Eteraf Oskuei T, Najafi N. Natural honey: a new and potent anti-angiogenic agent in the air pouch model of inflammation; 2013.
9. Safitri E, Utama S, Widiyatno TV, Sandhika W, Prasetyo RH. Auto-regeneration of mice testicle seminiferous tubules due to malnutrition based on stem cells mobilization using honey. Asian Pacific J Reproduction 2016;5:31-5.
10. Wikström AK, Larsson A, Eriksson UJ, Nash P, Norden Lindeberg S, Olovsson M. Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset preeclampsia. Obstetrics Gynecol 2007;109:1368–74.
11. Carmen R, Bacarea A, Hutanu A, Gabor R, Dobreanu M. Placental growth factor, soluble fms-like tyrosine kinase 1, soluble endoglin, IL-6, and IL-16 as biomarkers in preeclampsia. Hindawi Publishing Corporation Obstetrics and Gynecology International; 2016.
12. Roque L, Novoa J. Soluble endoglin: a biomarker or a protagonist in the pathogenesis of preeclampsia. Port J Nephrol Hypert 2014;28:3.
13. Pal AD. A novel insight into anti-angiogenic foods. Int J Food Sci Nutr 2007;2:87-93.